Ching-Shih Chen PhD

Ching-Shih Chen PhD
ProfessorCollege of Pharmacychen.844@osu.edu
336 Parks Hall 500 W 12th Avenue Columbus Ohio 43210
Phone:614-688-4008Fax: (614) 688-8556
  • Molecular Carcinogenesis and Chemoprevention

Research Description

Dr. Chen's research focuses on exploring signaling pathways that govern cancer cell survival as targets for drug discovery and design. He employs a multidisciplinary approach to identify new molecular targets by combining a wide range of expertise encompassing synthetic medicinal chemistry, molecular and cell biology, molecular pharmacology, and animal models in his research team. His laboratory has developed a series of novel small-molecule agents that target different molecular defects related to kinase signaling, epigenetics, and cell metabolism in cancer cells, including phosphoinositide-dependent kinase (PDK)-1/Akt inhibitors, histone deacetylase (HDAC) inhibitors, Bcl-2/Bcl-xL inhibitors, protein kinase C delta activators, AMPK activators, and glucose transporter inhibitors. These novel agents mediate antiproliferative effects through mechanisms distinct from that of conventional chemotherapeutic regimens, which will provide a rational approach for molecular targeted cancer therapy.

Current Publications

  • Mao Y, Wang J, Zhao Y, Yan R, Li H, Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N, Phelps MAQuantification of OSU-2S, a novel derivative of FTY720, in mouse plasma by liquid chromatography-tandem mass spectrometry.J Pharm Biomed Anal 98 160-5 9/1/2014
  • Chou CC, Lee KH, Lai IL, Wang D, Mo X, Kulp SK, Shapiro CL, Chen CSAMPK Reverses the Mesenchymal Phenotype of Cancer Cells by Targeting the Akt-MDM2-Foxo3a Signaling Axis.Cancer Res 74 4783-95 9/1/2014
  • Jones J, Andritsos L, Maddocks K, Wu CH, Chen CS, Lehman A, Zhang X, Lapalombella R, Byrd JC, El-Gamal D, Williams K, LaFollette TD, Cannon M, Blachly JS, Zhong Y, Woyach JA, Williams E, Awan FTPKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.Blood 124 1481-91 8/28/2014
  • Chen CS, Lee RJ, Byrd JC, Lee LJ, Muthusamy N, Mani R, Mao Y, Frissora FW, Chiang CL, Wang J, Zhao Y, Wu Y, Yu B, Yan R, Mo X, Yu L, Flynn J, Jones J, Andritsos L, Baskar S, Rader C, Phelps MATumor antigen ROR1 targeted drug delivery mediated selective leukemic but not normal B cell cytotoxicity in chronic lymphocytic leukemia.Leukemia in press 6/20/2014
  • Liu FL, Hsu JL, Lee YJ, Dong YS, Kung FL, Chen CS, Guh JHCalanquinone A induces anti-glioblastoma activity through glutathione-involved DNA damage and AMPK activation.Eur J Pharmacol 730 90-101 5/5/2014
  • Chou CC, Salunke SB, Kulp SK, Chen CSProspects on strategies for therapeutically targeting oncogenic regulatory factors by small-molecule agents.J Cell Biochem 115 611-24 4/1/2014
  • Chen CH, Chen MC, Wang JC, Tsai AC, Chen CS, Liou JP, Pan SL, Teng CMSynergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.Clin Cancer Res 20 1274-87 3/1/2014
  • Mao Y, Wang J, Zhao Y, Wu Y, Kwak KJ, Chen CS, Byrd JC, Lee RJ, Phelps MA, Lee LJ, Muthusamy NA novel liposomal formulation of FTY720 (fingolimod) for promising enhanced targeted delivery.Nanomedicine 10 393-400 2/1/2014
  • Hensley PJ, Desiniotis A, Wang C, Stromberg A, Chen CS, Kyprianou NNovel pharmacologic targeting of tight junctions and focal adhesions in prostate cancer cells.PLoS One 9 e86238 1/1/2014
  • Jiang Y, Wang J, Rozewski DM, Kolli S, Wu CH, Chen CS, Yang X, Hofmeister CC, Byrd JC, Johnson AJ, Phelps MASensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue.J Pharm Biomed Anal 88 262-8 1/1/2014
  • Chu PC, Kulp SK, Chen CSInsulin-like growth factor-I receptor is suppressed through transcriptional repression and mRNA destabilization by a novel energy restriction-mimetic agent.Carcinogenesis 34 2694-705 12/1/2013
  • Chan SH, Leu WJ, Hsu LC, Chang HS, Hwang TL, Chen IS, Chen CS, Guh JHReevesioside F induces potent and efficient anti-proliferative and apoptotic activities through Na⁺/K⁺-ATPase α3 subunit-involved mitochondrial stress and amplification of caspase cascades.Biochem Pharmacol 86 1564-75 12/1/2013
  • Bernot KM, Siebenaler RF, Whitman SP, Zorko NA, Marcucci GG, Santhanam R, Ahmed EH, Ngangana M, McConnell KK, Nemer JS, Brook DL, Kulp SK, Chen CS, Frankhouser D, Yan P, Bundschuh R, Zhang X, Dorrance AM, Dickerson KE, Jarjoura D, Blum W, Marcucci G, Caligiuri MAToward personalized therapy in AML: in vivo benefit of targeting aberrant epigenetics in MLL-PTD-associated AML.Leukemia 27 2379-82 12/1/2013
  • Huang Z, Kang TH, Soong RS, Knoff J, Axenfeld E, Wang C, Alvarez RD, Chen CS, Hung CF, Wu TC, Lee SYHistone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.J Mol Med (Berl) 91 1221-31 10/1/2013
  • Paisie CA, Eiring AM, Ma Y, Mao HC, Zhang B, Wunderlich M, May PC, Sun C, Saddoughi SA, Bielawski J, Blum W, Klisovic RB, Solt JA, Byrd JC, Volinia S, Cortes J, Huettner CS, Koschmieder S, Holyoake TL, Devine S, Caligiuri MA, Croce CM, Garzon R, Ogretmen B, Arlinghaus RB, Chen CS, Bittman R, Neviani P, Harb JG, Oaks JJ, Santhanam R, Walker CJ, Ellis JJ, Ferenchak G, Dorrance AM, Hokland P, Roy DC, Milojkovic D, Apperley J, Goldman JM, Reid A, Mulloy JC, Bhatia R, Marcucci G, Perrotti DPP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.J Clin Invest 123 4144-57 10/1/2013
  • Ma Y, McCarty SK, Kapuriya NP, Brendel VJ, Wang C, Zhang X, Jarjoura D, Saji M, Chen CS, Ringel MDDevelopment of p21 activated kinase-targeted multikinase inhibitors that inhibit thyroid cancer cell migration.J Clin Endocrinol Metab 98 E1314-22 8/1/2013
  • Yen MC, Weng TY, Chen YL, Lin CC, Chen CY, Wang CY, Chao HL, Chen CS, Lai MDAn HDAC inhibitor enhances cancer therapeutic efficiency of RNA polymerase III promoter-driven IDO shRNA.Cancer Gene Ther 20 351-7 6/1/2013
  • Yang YL, Huang PH, Chiu HC, Kulp SK, Chen CS, Kuo CJ, Chen HD, Chen CSHistone deacetylase inhibitor AR42 regulates telomerase activity in human glioma cells via an Akt-dependent mechanism.Biochem Biophys Res Commun 435 107-12 5/24/2013
  • Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, James Lee L, Jacob S, Mrózek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci GIncreased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia.Leukemia 27 871-8 4/1/2013
  • Berman-Booty LD, Chu PC, Thomas-Ahner JM, Bolon B, Wang D, Yang T, Clinton SK, Kulp SK, Chen CSSuppression of prostate epithelial proliferation and intraprostatic progrowth signaling in transgenic mice by a new energy restriction-mimetic agent.Cancer Prev Res (Phila) 6 232-41 3/1/2013
  • Chang LS, Burns SS, Akhmametyeva EM, Oblinger JL, Bush ML, Huang J, Senner V, Chen CS, Jacob A, Welling DBHistone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.Cancer Res 73 792-803 1/15/2013
  • Lee SL, Chou CC, Chuang HC, Hsu EC, Chiu PC, Kulp SK, Byrd JC, Chen CSFunctional Role of mTORC2 versus Integrin-Linked Kinase in Mediating Ser473-Akt Phosphorylation in PTEN-Negative Prostate and Breast Cancer Cell Lines.PLoS One 8 e67149 1/1/2013
  • Wang H, Lee SL, Yang HC, Chiu HC, Kapuriya N, Wang D, Kulp SK, Chen CS, Huang PH, Chuang HC, Chou CCVitamin E facilitates the inactivation of the kinase Akt by the phosphatase PHLPP1.Sci Signal 6 ra19 1/1/2013
  • Chu PC, Chuang HC, Kulp SK, Chen CSThe mRNA-stabilizing factor HuR protein is targeted by β-TrCP protein for degradation in response to glycolysis inhibition.J Biol Chem 287 43639-50 12/21/2012
  • Booth L, Cruickshanks N, Ridder T, Chen CS, Grant S, Dent POSU-03012 interacts with lapatinib to kill brain cancer cells.Cancer Biol Ther 13 1501-11 12/1/2012
  • Lin HY, Kuo YC, Weng YI, Lai IL, Huang TH, Lin SP, Niu DM, Chen CSActivation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent.Prostate 72 1767-78 12/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu